Omafwon Injection

Adult administration

Children aged 12 years and older and adults - For patients in normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg of amino acids per day (0.10-0.15 g/kg as nitrogen) - For patients under moderate to severe metabolic stress regardless of nutritional imbalance: 0.9-1.6 g/kg of amino acids per day (0.15-0.25 g/kg as nitrogen) Dosage: This medication 13-31

Child administration

Children aged 2-11 years Dosage: Pediatric patients have greater variability than adult patients, so dosages of up to 35 mL/kg of this medication should be regularly adjusted based on need. Administration rate: 2.4 mL/kg per hour.

This medication should be used strictly according to a doctor's instructions, and it must be discontinued immediately if any anaphylactic reactions such as fever, chills, rash, or difficulty breathing occur. When used together with intravenous calcium-containing preparations, precipitates may form, so they should not be administered simultaneously using the same infusion apparatus, and the infusion line should be thoroughly washed with an appropriate solution. Special care is needed for premature or low-weight infants, and extreme caution is advised when administering to premature infants with severe respiratory diseases as fatalities have been reported. Patients with allergies to fish, eggs, soybeans, peanut protein, or components of this medication, as well as those with severe liver, kidney, or blood diseases, acute shock, or uncontrolled hyperglycemia should not use this medication. Patients with conditions that may affect lipid metabolism, such as renal failure, diabetes, or liver dysfunction, should be administered with caution, and during administration, blood triglyceride levels, electrolyte concentrations, blood glucose, and liver enzyme levels should be regularly monitored for adverse reactions. This medication may cause various side effects such as hyperlipidemia, allergic reactions, blood pressure changes, gastrointestinal symptoms, etc. Therefore, any abnormal symptoms should immediately be discussed with a healthcare professional. It is particularly recommended not to administer to children under 2 years of age, and caution should be exercised in pregnant or breastfeeding women as the safety of this medication is not established; it should only be used when absolutely necessary. Ensure aseptic conditions during administration, do not use if the package or solution is damaged or cloudy, and in case of overdose, reduce or stop the infusion rate and seek appropriate emergency treatment. Additionally, insulin administration may be necessary depending on the patient's condition, and careful observation is needed as fluid overload or electrolyte imbalances can occur.

Serious side effects

Hives, severe swelling, chest tightness, difficulty breathing, anaphylactic reactions, skin peeling, oral/ocular mucosal pain, severe skin reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever, yellowing of the skin or eyes (jaundice), extreme lethargy, liver abnormalities (jaundice), sudden and very severe headaches, lightning-like headaches, seizures, altered consciousness, vision problems, paralysis,

Mild side effects

Loss of appetite, nausea, vomiting, increased plasma liver enzyme levels, thrombotic vein inflammation, hypotension, hypertension, slight increase in body temperature, chills, headache, dizziness, skin rash, flushing, cyanosis, pallor, pain (in the neck, back, bones, chest, lower back), nausea, vomiting, chills, sweating, elevated body temperature, hyperglycemia, constipation, diarrhea, indigestion, edema, generalized weakness, hypoglycemia, increased urination, venous inflammation, extravasation at the injection site, voice disturbances,

This medication should be stored in a well-sealed container to prevent air ingress and kept in a cool place below 25°C. Care should be taken not to freeze, and exposure to excessively hot or cold environments should be avoided.

Appearance

It consists of a colorless, transparent plastic inner bag divided into 3 segments and an outer packaging with an oxygen absorber placed in between. Each inner bag contains a colorless to pale yellow transparent amino acid solution.

Package unit

986mL (A solution 500mL, B solution 298mL, C solution 188mL), 1477mL (A solution 750mL, B solution 446mL, C solution 281mL), 1970mL (A solution 1000mL, B solution 595mL, C solution 375mL)